Dennis Kyle, GRA Eminent Scholar in Antiparasitic Drug Discovery and director of the Center for Tropical and Emerging Global Diseases, was awarded Medicines for Malaria Venture Project of the Year 2016 jointly with two other drug discovery research teams.
The award recognizes his progress in developing new assay platforms to test compounds for activity against the dormant liver stages of malaria. These new assays are making it possible to screen and identify novel compounds that could prevent relapse and protect against Plasmodium vivax and Plasmodium ovale malaria.
“There is a huge unmet medical need for new medicines to stop the debilitating relapse of P. vivax malaria,” said Dr. David Reddy, MMV’s CEO. “Each episode keeps a child or adult from school or work for at least three days. This places a huge burden on countries and communities that can afford it least. These three research teams have made impressive strides towards helping meet this unmet need and are deserving recipients of MMV’s Project of the Year 2016.”